To develop and evaluate a quantitative lateral flow immunoassay for measuring plasma soluble AXL (sAXL) as a potential aid to pancreatic ductal adenocarcinoma (PDAC) diagnosis.
Approach:
Assay development: Researchers optimized a colorimetric strip using capture and detection antibodies and anti-biotin gold nanoparticles. They first assessed the immunoreagents in a sandwich ELISA.
Evaluation: The lateral flow assay was tested on plasma from 20 patients with PDAC and 20 healthy controls and compared with ELISA measurements.
Key Findings:
The sandwich ELISA showed a linear sAXL response and a reported detection limit of 0.16 ng/mL.
The lateral flow assay detected higher sAXL concentrations in the PDAC group and statistically differentiated patients from healthy controls.
Interpretation:
The study provides an early evaluation of a quantitative lateral flow format for plasma sAXL measurement; it does not establish the assay for routine diagnosis or screening.
Limitations:
The clinical cohort was small and included only patients with PDAC and healthy controls.
The assay was not evaluated against chronic pancreatitis, benign pancreatic disease, other cancers, or inflammatory conditions.
Sensitivity, specificity, clinical cutoffs, reference intervals, and performance across disease stages remain to be established in larger, independent, multicenter studies.
Conclusion:
The findings do not support replacing imaging, histopathology, cytology, or laboratory ELISA with this assay.